Sunday, August 22, 2021 7:23:51 PM
$RXMD Due Diligence - Verifiable Facts (8/22/2021)
$RXMD is a UNICORN and Significantly Undervalued! IMO, decide for yourself...
2020 $40.6M REVENUE, walking the profitability line from multiple revenue streams/companies: PharmCoRx (pharmacy) and ClearMetrX (pharmaceutical technology)
The best is yet to come! The quiet period is weighing on investor confidence; I believe there are simply delays, which includes debt settlement. The Iliad Research convertible loan does not allow for cash settlement. RXMD hasn't been able to renegotiate, but is trying. Iliad is under SEC investigation for these loans, and might change their mind?? The very fact that we have unsettled debt with Iliad could be the reason for the delay with the SEC S-1 approval. Regardless of if that is true, the dilution will end, and just a pop to fair value based on today's fundamentals will be a nice adjustment for shareholders. In the meantime, shares are being converted at a discount and sold cheap. It seems aggressive and hastened. For those not in, current prices are very cheap; it is the daily 10% dilution that is holding this down. IMO
* 2021 should turn profitable, IMO, because of operations consolidations, now complete, and ClearMetrX expansion.
* During the 2021 Q2 a forward looking statement estimated that the company should be valued at $1B in 5 years. That is aggressive and it's unlike them to make such a bold prediction. I believe it is the technology revenue that makes them so bullish. And those profits will likely bring PharmCoRx expansion.
* CEO letter on 9/2020, PR; mentions organic path to $100M REVENUE! That's from a year ago, FYI, so expect long term.
* S-1 FILED with SEC on 11/9/2021, PR; confidential to the public, to protect their secret expansion plan.
* $RXMD is in MANDATORY Quiet Period before expected NASDAQ Uplist.
* $RXMD has stated that transformative changes are coming!
* $RXMD is expanding to technology sales, telehealth, and pharmaceutical processing with metrics.
* RXMD attempted and failed to implement Keycentrix Newleaf, a best-in-class pharmacy software solution, for ClearMetrX, 2/2021 PR; RXMD found that Newleaf didn't support RXMD's unique pharmacy needs as well as their current system; and the current system is now integrated with ClearMetrX by our partner, MyApps.
* MyApps Partnership benefits both companies, implementing RXMD technology initiatives, including ClearMetrX. RXMD wanted to acquire MyApps for shares, but the shareholders were vocally unhappy, and RXMD announced a win-win Partnership instead, PR.
* EagleForce Health Partnership announced 2/2021, PR; statement from EagleForce Health included. The $RXMD CEO stated that this partnership will "scale more of our operations in a geographically agnostic manner" (Telehealth Web! National! International?)
* Progressive Care Announces Full Launch of New COVID-19 Digital Passport App, 7/2021 PR; Progressive Care Inc... a personalized healthcare services and technology company, is excited to announce the launch of the Company’s new myVax Passport, developed in partnership with EagleForce Health, LLC (“EagleForce”).
* OS only 525M!
* Market Cap still lower than fair value! Only 51% of REVENUE!
* $RXMD is worth $150M if sold Privately, it is easy to justify that number just based on REVENUE, assets, and growth momentum.
* Public company multiple should be at least 3X $450M with current initiatives, perhaps higher because of unknowns in confidential S-1, IMO
* $450M fair valuation puts PPS at $0.86! With NASDAQ uplist, technology expansion, and organic growth, speculation and momentum could drive PPS much higher, perhaps enough to uplist!! Eventually, IMO
* OTCQB Member Since 12/2017, Penny Stock Exempt, Transfer Agent Verified, Independent Directors
* No viable trips exist! $RXMD is a UNICORN! If you check it out, you'll see the value!!
RXMD Investor Deck 2021
CEO letter to shareholders with path to $100M REVENUE
PR RXMD Telehealth Partnership with EagleForce Health
EagleForce: Interoperability of healthcare... big data
EagleForce: Telehealth Partnerships
theeagleforce.net
MyApps Partnership, including CallingDr App and ClearMetrX
RXMD Annual Revenue Growth History 2013 - 2020
ProgressiveCareUS.com
PharmCoRx.com
ClearMetrX.com
facebook.com/ProgressiveCareUS
facebook.com/PharmCoRx
facebook.com/ClearMetrX
twitter.com/ProgressCareUS
twitter.com/PharmCoRx
twitter.com/ClearMetrX
otcmarkets.com/stock/RXMD/news
otcmarkets.com/stock/RXMD/disclosure
otcmarkets.com/stock/RXMD/security
investorshub.advfn.com/Progressive-Care-Inc-RXMD-19843
$RXMD has been under attack for years, ever since the former CEO took action to force naked shorts to cover. IMO, it contributes to the low PPS.
Progressive Care Updates Shareholders on the Status of Naked Shorts
May 1, 2018.
https://www.globenewswire.com/news-release/2018/05/01/1494089/0/en/Progressive-Care-Updates-Shareholders-on-the-Status-of-Naked-Shorts.html
High Speed Trading Firm... going to war with the SEC
Message Board Thread
Bring on the Profits!
Good Luck RXMD!
$$$,$$$,$$$
$RXMD is a UNICORN and Significantly Undervalued! IMO, decide for yourself...
2020 $40.6M REVENUE, walking the profitability line from multiple revenue streams/companies: PharmCoRx (pharmacy) and ClearMetrX (pharmaceutical technology)
The best is yet to come! The quiet period is weighing on investor confidence; I believe there are simply delays, which includes debt settlement. The Iliad Research convertible loan does not allow for cash settlement. RXMD hasn't been able to renegotiate, but is trying. Iliad is under SEC investigation for these loans, and might change their mind?? The very fact that we have unsettled debt with Iliad could be the reason for the delay with the SEC S-1 approval. Regardless of if that is true, the dilution will end, and just a pop to fair value based on today's fundamentals will be a nice adjustment for shareholders. In the meantime, shares are being converted at a discount and sold cheap. It seems aggressive and hastened. For those not in, current prices are very cheap; it is the daily 10% dilution that is holding this down. IMO
* 2021 should turn profitable, IMO, because of operations consolidations, now complete, and ClearMetrX expansion.
* During the 2021 Q2 a forward looking statement estimated that the company should be valued at $1B in 5 years. That is aggressive and it's unlike them to make such a bold prediction. I believe it is the technology revenue that makes them so bullish. And those profits will likely bring PharmCoRx expansion.
* CEO letter on 9/2020, PR; mentions organic path to $100M REVENUE! That's from a year ago, FYI, so expect long term.
* S-1 FILED with SEC on 11/9/2021, PR; confidential to the public, to protect their secret expansion plan.
* $RXMD is in MANDATORY Quiet Period before expected NASDAQ Uplist.
* $RXMD has stated that transformative changes are coming!
* $RXMD is expanding to technology sales, telehealth, and pharmaceutical processing with metrics.
* RXMD attempted and failed to implement Keycentrix Newleaf, a best-in-class pharmacy software solution, for ClearMetrX, 2/2021 PR; RXMD found that Newleaf didn't support RXMD's unique pharmacy needs as well as their current system; and the current system is now integrated with ClearMetrX by our partner, MyApps.
* MyApps Partnership benefits both companies, implementing RXMD technology initiatives, including ClearMetrX. RXMD wanted to acquire MyApps for shares, but the shareholders were vocally unhappy, and RXMD announced a win-win Partnership instead, PR.
* EagleForce Health Partnership announced 2/2021, PR; statement from EagleForce Health included. The $RXMD CEO stated that this partnership will "scale more of our operations in a geographically agnostic manner" (Telehealth Web! National! International?)
* Progressive Care Announces Full Launch of New COVID-19 Digital Passport App, 7/2021 PR; Progressive Care Inc... a personalized healthcare services and technology company, is excited to announce the launch of the Company’s new myVax Passport, developed in partnership with EagleForce Health, LLC (“EagleForce”).
* OS only 525M!
* Market Cap still lower than fair value! Only 51% of REVENUE!
* $RXMD is worth $150M if sold Privately, it is easy to justify that number just based on REVENUE, assets, and growth momentum.
* Public company multiple should be at least 3X $450M with current initiatives, perhaps higher because of unknowns in confidential S-1, IMO
* $450M fair valuation puts PPS at $0.86! With NASDAQ uplist, technology expansion, and organic growth, speculation and momentum could drive PPS much higher, perhaps enough to uplist!! Eventually, IMO
* OTCQB Member Since 12/2017, Penny Stock Exempt, Transfer Agent Verified, Independent Directors
* No viable trips exist! $RXMD is a UNICORN! If you check it out, you'll see the value!!
RXMD Investor Deck 2021
CEO letter to shareholders with path to $100M REVENUE
PR RXMD Telehealth Partnership with EagleForce Health
EagleForce: Interoperability of healthcare... big data
EagleForce: Telehealth Partnerships
theeagleforce.net
MyApps Partnership, including CallingDr App and ClearMetrX
RXMD Annual Revenue Growth History 2013 - 2020
ProgressiveCareUS.com
PharmCoRx.com
ClearMetrX.com
facebook.com/ProgressiveCareUS
facebook.com/PharmCoRx
facebook.com/ClearMetrX
twitter.com/ProgressCareUS
twitter.com/PharmCoRx
twitter.com/ClearMetrX
otcmarkets.com/stock/RXMD/news
otcmarkets.com/stock/RXMD/disclosure
otcmarkets.com/stock/RXMD/security
investorshub.advfn.com/Progressive-Care-Inc-RXMD-19843
$RXMD has been under attack for years, ever since the former CEO took action to force naked shorts to cover. IMO, it contributes to the low PPS.
Progressive Care Updates Shareholders on the Status of Naked Shorts
May 1, 2018.
https://www.globenewswire.com/news-release/2018/05/01/1494089/0/en/Progressive-Care-Updates-Shareholders-on-the-Status-of-Naked-Shorts.html
High Speed Trading Firm... going to war with the SEC
Message Board Thread
Bring on the Profits!
Good Luck RXMD!
$$$,$$$,$$$
I'm here to discover news and share opinions with other investors. All of my posts are my opinions and derivatives.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.